title: Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
abstract: Erythropoiesis stimulating agents (ESAs) have revolutionized the management of anemia of chronic kidney disease (CKD). Peginesatide is an investigational pegylated, peptide-based, once-monthly ESA for increasing and maintaining hemoglobin (Hb). In phase 2 studies, peginesatide increases and maintains target Hb levels in patients with CKD, both those on hemodialysis and those not on hemodialysis; phase 3 trials have recently been completed. This article discusses unmet needs in the management of anemia of CKD, presents peginesatide attributes, reviews the results of select peginesatide clinical studies, and discusses the potential value of peginesatide as an alternative anemia management option.
authors.affiliation: Satellite Healthcare, Inc., San Jose, CA, USA. dosss@satellitehealth.com
authors.forename: Sheila
authors.initials: S
authors.lastname: Doss
authors.forename: Brigitte
authors.initials: B
authors.lastname: Schiller
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D014481:United States
chemical_list: D006397:Hematinics; D010455:Peptides; C556270:peginesatide